DOMH Stock Overview
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Dominari Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.80 |
| 52 Week High | US$3.76 |
| 52 Week Low | US$1.76 |
| Beta | 0.94 |
| 1 Month Change | 28.44% |
| 3 Month Change | 24.35% |
| 1 Year Change | -23.91% |
| 3 Year Change | -82.06% |
| 5 Year Change | -95.19% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
AIkido continues to buyback more shares
Oct 05AIkido Pharma's subsidiary agrees to buy broker-dealer firm
Sep 12Alkido Pharma shareholders proposes to acquire company at $8/share in cash
Aug 09AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans
May 04
AIkido Pharma: Advancing Anticancer And Antiviral Therapies
Feb 10AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans
Jan 14Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation
Sep 29We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth
Jun 05AIkido Pharma's stock surges on psilocybin patent license agreement
Jan 06Shareholder Returns
| DOMH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.2% | -4.2% | -3.7% |
| 1Y | -23.9% | -2.0% | 20.5% |
Return vs Industry: DOMH underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: DOMH underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| DOMH volatility | |
|---|---|
| DOMH Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DOMH's share price has been volatile over the past 3 months.
Volatility Over Time: DOMH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 27 | Anthony Hayes | www.aikidopharma.com |
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company’s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Dominari Holdings Inc. Fundamentals Summary
| DOMH fundamental statistics | |
|---|---|
| Market cap | US$16.50m |
| Earnings (TTM) | -US$22.88m |
| Revenue (TTM) | US$2.04m |
8.1x
P/S Ratio-0.7x
P/E RatioIs DOMH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DOMH income statement (TTM) | |
|---|---|
| Revenue | US$2.04m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.04m |
| Other Expenses | US$24.92m |
| Earnings | -US$22.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.86 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,122.22% |
| Debt/Equity Ratio | 0% |
How did DOMH perform over the long term?
See historical performance and comparison